On October 22, the official website of the China Drug Administration revealed that Suhuan®, an umeponium bromide inhalation powder independently developed by the core Chinese biopharmaceutical company Zhengda Tianqing, was approved for marketing for long-term maintenance treatment of chronic obstructive pulmonary disease.

On October 22, the official website of the China Drug Administration revealed that Suhuan®, an umeponium bromide inhalation powder independently developed by the core Chinese biopharmaceutical company Zhengda Tianqing, was approved for marketing for long-term maintenance treatment of chronic obstructive pulmonary disease.